{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T15:52:27Z","timestamp":1770997947105,"version":"3.50.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2003,9,12]],"date-time":"2003-09-12T00:00:00Z","timestamp":1063324800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1007\/s00296-003-0392-2","type":"journal-article","created":{"date-parts":[[2004,3,19]],"date-time":"2004-03-19T15:29:40Z","timestamp":1079710180000},"page":"9-14","source":"Crossref","is-referenced-by-count":16,"title":["Cost-effectiveness analysis of NSAIDs, NSAIDs with concomitant therapy to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis"],"prefix":"10.1007","volume":"25","author":[{"given":"Hyung Ran","family":"Yun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Cheol","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2003,9,12]]},"reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJM199906173402407","volume":"340","author":"Wolfe","year":"1999","unstructured":"Wolfe MM, Lichtenstein DR, Singh G (1999) Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340:1888?1899","journal-title":"N Engl J Med"},{"key":"CR2","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/art.1780311118","volume":"31","author":"Paulus","year":"1988","unstructured":"Paulus HE (1988) FDA Arthritis Advisory Committee meeting: serious gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs, etc. Arthritis Rheum 31:1450?1451","journal-title":"Arthritis Rheum"},{"key":"CR3","first-page":"6","volume":"28","author":"Fries","year":"1991","unstructured":"Fries JF (1991) NSAIDS gastropathy: the second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 28:6?10","journal-title":"J Rheumatol"},{"key":"CR4","first-page":"798","volume":"145","author":"Fries","year":"1986","unstructured":"Fries JF, McShane DJ (1986) ARAMIS (the American Rheumatism Association Medical Information System). A prototypical national chronic-disease data bank. West J Med 145:798?804","journal-title":"West J Med"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(88)92892-9","volume":"2","author":"Graham","year":"1988","unstructured":"Graham DY, Agawal NM, Roth SH (1988) Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial. Lancet 2:1277?1280","journal-title":"Lancet"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-123-4-199508150-00001","volume":"123","author":"Silverstein","year":"1995","unstructured":"Silverstein FE, Graham DY, Senior JR, et al (1995) Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind placebo-controlled trial. Ann Intern Med 123:241?249","journal-title":"Ann Intern Med"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/jama.1990.03450010045028","volume":"264","author":"Edelson","year":"1990","unstructured":"Edelson JT, Tosteson AN, Sax P (1990) Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA 264:41?47","journal-title":"JAMA"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/art.1780360404","volume":"36","author":"Gabriel","year":"1993","unstructured":"Gabriel SE, Jaakkimainen RL, Bombardier C (1993) The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated gastrointestinal events. Arthritis Rheum 36:447?459","journal-title":"Arthritis Rheum"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1001\/archinte.1994.00420180022003","volume":"154","author":"Stucki","year":"1994","unstructured":"Stucki G, Johannesson M, Liang MH (1994) Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? A review of conflicting economic evaluations. Arch Intern Med 154:2020?2025","journal-title":"Arch Intern Med"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1001\/archinte.1996.00440190069008","volume":"156","author":"Koch","year":"1996","unstructured":"Koch M, Dezi A, Ferrario F, Capurso L (1996) Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. A meta-analysis of randomized controlled clinical trials. Arch Intern Med 156:2321?2332","journal-title":"Arch Intern Med"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/1529-0131(199801)41:1<16::AID-ART3>3.0.CO;2-4","volume":"41","author":"Maetzel","year":"1998","unstructured":"Maetzel A, Ferraz MB, Bombardier C (1998) The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs. Arthritis Rheum 41:16?25","journal-title":"Arthritis Rheum"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3109\/00365529609010347","volume":"31","author":"Ekstr\ufffdm","year":"1996","unstructured":"Ekstr\ufffdm P, Carling L, Wetterhus S, et al (1996) Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 31:753?758","journal-title":"Scand J Gastroenterol"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2036.1998.00288.x","volume":"12","author":"Cullen","year":"1998","unstructured":"Cullen D, Bardhan KD, Eisner M, et al (1998) Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Alliment Pharmacol Ther 12:135?140","journal-title":"Alliment Pharmacol Ther"},{"key":"CR14","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199803123381104","volume":"338","author":"Yeomans","year":"1998","unstructured":"Yeomans ND, Tulassay Z, Juh\ufffdsz L, et al (1998) A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338:719?726","journal-title":"N Engl J Med"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1111\/j.1572-0241.2000.02194.x","volume":"95","author":"Goldstein","year":"2000","unstructured":"Goldstein JL, Silverstein FE, Agrawal NM, et al (2000) Reduced risk of upper gastrointestinal ulcer complication with celecoxib, a novel COX-2 inhibitor. Am J Gastroenterol 95:1681?1690","journal-title":"Am J Gastroenterol"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1001\/jama.282.20.1929","volume":"282","author":"Langman","year":"1999","unstructured":"Langman MJ, Jensen DM, Watson DJ, et al (1999) Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 282:1929?1933","journal-title":"JAMA"},{"key":"CR17","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0016-5085(99)70334-3","volume":"117","author":"Laine","year":"1999","unstructured":"Laine L, Harper S, Simon T, et al (1999) A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 117:776?783","journal-title":"Gastroenterology"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/1529-0131(199911)42:11<2293::AID-ANR6>3.0.CO;2-1","volume":"42","author":"Kristiansen","year":"1999","unstructured":"Kristiansen IS, Kvien TK, Nord E (1999) Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis. Arthritis Rheum 42:2293?2302","journal-title":"Arthritis Rheum"},{"key":"CR19","unstructured":"National Institute for Clinical Excellence (2001) Guidance on the use of cyclo-oxygenase (COX) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for OA and RA. Technology Appraisal Guidance No. 27. National Institute for Clinical Excellence, London"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/0272989X9301300409","volume":"13","author":"Sonnenberg","year":"1993","unstructured":"Sonnenberg FA, Beck JR (1993) Markov models in medical decision making: a practical guide. Med Decis Making 13:322?338","journal-title":"Med Decis Making"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/ard.58.4.220","volume":"58","author":"Dougados","year":"1999","unstructured":"Dougados M, Combe B, Cantagrel A, et al (1999) Combination therapy in early rheumatoid arthritis: a randomized, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 58:220?225","journal-title":"Ann Rheum Dis"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/1529-0131(200001)43:1<22::AID-ANR4>3.0.CO;2-9","volume":"43","author":"Anderson","year":"2000","unstructured":"Anderson JJ, Wells G, Verhoeven AC, Felson DT (2000) Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 43:22?29","journal-title":"Arthritis Rheum"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/art.1780370408","volume":"37","author":"Wolfe","year":"1994","unstructured":"Wolfe F, Mitchell DM, Sibley JT, et al (1994) The mortality of rheumatoid arthritis. Arthritis Rheum 37:481?494","journal-title":"Arthritis Rheum"},{"key":"CR24","first-page":"1876","volume":"27","author":"Bensen","year":"2000","unstructured":"Bensen WG, Zhao SZ, Burke TA, et al (2000) Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. J Rheumatol 27:1876?1883","journal-title":"J Rheumatol"},{"key":"CR25","unstructured":"U.S. Bureau of Labor Statistics (1999) 1999 Consumer Price Index for Hospital and Related Services, Physician Services, Medical Care Services, Professional Medical Services, Drugs, and Medical Care Commodities. U.S. Department of Labor, Washington, DC"},{"key":"CR26","unstructured":"1999 Red Book (1999) Medical Economics, Montvale, NJ"},{"key":"CR27","doi-asserted-by":"crossref","unstructured":"Lipscomb J, Weinstein MC, Torrance GW (1996) Time preference. In: Gold MR, Siegel JE, Russel LB, Weinstein MC (eds) Cost-effectiveness in health and medicine. Oxford University Press, Oxford, pp 214?246","DOI":"10.1093\/oso\/9780195108248.003.0007"},{"key":"CR28","first-page":"Williamstown","volume":"Software","author":"Decision","year":"1999","unstructured":"Decision analysis (1999) TreeAge Software: Williamstown, MA","journal-title":"TreeAge"},{"key":"CR29","unstructured":"Kristiansen IS, Odense TK (2000) Cost-effectiveness of replacing diclofenac 75\ufffdmg bid by celecoxib 200\ufffdmg bid in patients with rheumatoid arthritis (Abstract). Arthritis Rheum 43[Suppl 9]: S146"},{"key":"CR30","doi-asserted-by":"crossref","unstructured":"Burke TA, Zabinski RA, Pettitt D, Maniadakis N, Maurath CJ, Goldstein JL (2001) A framework for evaluating the clinical consequences of initial therapy with NSAIDs, NSAIDs plus gastroprotective agents, or celecoxib in the treatment of arthritis. Pharmacoeconomics 19[Suppl 1]: 33?47","DOI":"10.2165\/00019053-200119001-00003"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"344","DOI":"10.7326\/0003-4819-123-5-199509010-00004","volume":"123","author":"Raskin","year":"1995","unstructured":"Raskin JB, White RH, Jackson JE, et al (1995) Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens. Ann Intern Med 123:344?350","journal-title":"Ann Intern Med"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJM199605303342204","volume":"334","author":"Taha","year":"1996","unstructured":"Taha AS, Hudson N, Hawkey CJ, et al (1996) Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs. N Engl J Med 334:1435?1439","journal-title":"N Engl J Med"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1053\/gast.1997.v112.agast972143","volume":"112","author":"Graham","year":"1997","unstructured":"Graham DY (1997) High-dose famotidine for prevention of NSAID ulcers? Gastroenterology 112:2143?2145","journal-title":"Gastroenterology"},{"key":"CR34","first-page":"574","volume":"60","author":"Yun","year":"2001","unstructured":"Yun HR, Corzillius M, Kim SC, Bae SC (2001) Korean cost-effectiveness analysis of NSAIDs, NSAIDs with co-treatments to prevent gastrointestinal toxicity, and COX-2 specific inhibitors in the treatment of rheumatoid arthritis. Kor J Med 60:574?588","journal-title":"Kor J Med"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/jama.286.8.954","volume":"286","author":"Mukherjee","year":"2001","unstructured":"Mukherjee D, Nissen SE, Topol EJ (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286:954?959","journal-title":"JAMA"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1161\/hc4401.100078","volume":"104","author":"Konstam","year":"2001","unstructured":"Konstam MA, Weir MR, Reicin A, et al (2001) Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 104:2280?2288","journal-title":"Circulation"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0002-9149(01)02201-9","volume":"89","author":"Reicin","year":"2002","unstructured":"Reicin AS, Shapiro D, Sperling RS, Barr E, Yu Q (2002) Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol 89:204?209","journal-title":"Am J Cardiol"},{"key":"CR38","unstructured":"Walan A, Wahlqvist P (1993) Pharmacoeconomic aspects of nonsteroidal anti-inflammatory drug gastropathy [abstract]. Ital J Gastroenterol Hepatol 31[Suppl]: S79?S88"},{"key":"CR39","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0002-9343(91)90118-H","volume":"91","author":"Fries","year":"1991","unstructured":"Fries JF, Williams CA, Bloch DA, Michel BA (1991) Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models. Am J Med 91:213?222","journal-title":"Am J Med"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1001\/archinte.1997.00440390131016","volume":"157","author":"Miwa","year":"1997","unstructured":"Miwa LJ, Jones JK, Pathiyal A, Hatoum H (1997) Value of epidemiological studies in determining the true incidence of adverse events. The nonsteroidal anti-inflammatory drug story. Arch Intern Med 157:2129?2136","journal-title":"Arch Intern Med"},{"key":"CR41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2165\/00002018-199615010-00005","volume":"15","author":"Manoukian","year":"1996","unstructured":"Manoukian AV, Carson JL (1996) Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention. Drug Saf 15:64?71","journal-title":"Drug Saf"},{"key":"CR42","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1001\/archinte.156.21.2433","volume":"156","author":"Perez","year":"1996","unstructured":"Perez Gutthann S, Garcia Rodriguez LA, Raiford DS, Duque Oliart A, Ris Romeu J (1996) Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Arch Intern Med 156:2433?2439","journal-title":"Arch Intern Med"},{"key":"CR43","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1002\/art.1780400816","volume":"40","author":"Lanes","year":"1997","unstructured":"Lanes SF, Lanza LL, Radensky PW, et al (1997) Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthritis Rheum 40:1475?1481","journal-title":"Arthritis Rheum"},{"key":"CR44","first-page":"719","volume":"24","author":"Gabriel","year":"1997","unstructured":"Gabriel SE, Crowson CS, Campion ME, O'Fallon WM (1997) Direct medical costs unique to people with arthritis. J Rheumatol 24:719?725","journal-title":"J Rheumatol"},{"key":"CR45","first-page":"1051","volume":"24","author":"Clarke","year":"1997","unstructured":"Clarke AE, Zowall H, Levinton C, et al (1997) Direct and indirect medical costs incurred by Canadian patients with arthritis: a 12 year study. J Rheumatol 24:1051?1060","journal-title":"J Rheumatol"},{"key":"CR46","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/archinte.1989.00390050025005","volume":"149","author":"Bloom","year":"1989","unstructured":"Bloom BS (1989) Risk and cost of gastrointestinal side effects associated with nonsteroidal anti-inflammatory drugs. Arch Intern Med 149:1019?1022","journal-title":"Arch Intern Med"},{"key":"CR47","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00019053-199508030-00001","volume":"8","author":"Bond","year":"1995","unstructured":"Bond GR, Novak JE (1995) The human and economic cost of paracetamol (acetaminophen) overdose. Pharmacoeconomics 8:177?181","journal-title":"Pharmacoeconomics"},{"key":"CR48","doi-asserted-by":"crossref","first-page":"195","DOI":"10.7326\/0003-4819-127-3-199708010-00003","volume":"127","author":"Hamel","year":"1997","unstructured":"Hamel MB, Phillips RS, Davis RB, et al (1997) Outcomes and cost-effectiveness of initiating dialysis and continuing aggressive care in seriously ill hospitalized adults. SUPPORT Investigators. Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments. Ann Intern Med 127:195?202","journal-title":"Ann Intern Med"},{"key":"CR49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1177\/0272989X9301300202","volume":"13","author":"Fryback","year":"1993","unstructured":"Fryback DG, Dasbach EJ, Klein R, et al. (1993) The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making 13:89?102","journal-title":"Med Decis Making"},{"key":"CR50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/00365529609095547","volume":"21","author":"Talley","year":"1996","unstructured":"Talley NJ (1996) Quality of life in functional dyspepsia. Scan J Gastroenterol 31 Suppl 21:21?22","journal-title":"Scan J Gastroenterol 31 Suppl"},{"key":"CR51","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/1529-0131(200106)44:6<1467::AID-ART243>3.0.CO;2-6","volume":"44","author":"Ward","year":"2001","unstructured":"Ward MM (2001) Recent improvement in survival in patients with rheumatoid arthritis: better outcomes or different study designs? Arthritis Rheum 44:1467?1469","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-003-0392-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-003-0392-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-003-0392-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T18:40:40Z","timestamp":1705084840000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-003-0392-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,9,12]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["392"],"URL":"https:\/\/doi.org\/10.1007\/s00296-003-0392-2","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,9,12]]}}}